

**Amendments to and Listing of the Claims:**

1. to 35. (Canceled). 1

~~2~~ ~~36.~~ (Previously Presented) The interactive system according to claim ~~57~~, wherein the active substance is selected from the group consisting of a protein, a nucleic acid, a cellular signal substance, a partner of a biological or physiological affinity pair, a synthetic nickel-nitrilotriacetic acid (NiNTA) complex, a synthetically produced pharmacon, a synthetically produced active ingredient, and a marker for a biological or synthetic substance.

~~3~~ ~~37.~~ (Previously Presented) The interactive system according to claim ~~36~~, wherein the protein is selected from the group consisting of antigens, antibodies, tumor markers, surface antigens, ligands, receptors, surface-active cell fragments of bacteria, viral proteins and immune messenger substances. 2

~~4~~ ~~38.~~ (Previously Presented) The interactive system according to claim ~~36~~, wherein the marker is selected from the group consisting of a fluorescent or chemiluminescent substance, an expression sequence code (EST) and an enzyme. 2

39. to 41. (Canceled).

~~5~~ ~~42.~~ (Previously Presented) The interactive system according to claim ~~57~~, wherein the surface is a membrane, a porous or solid microparticle, a magnetic microparticle, a filter mat, a fibrous material, a spun material or a combination thereof, or a coating made from a natural or synthetic substance. 1

~~6~~ ~~43.~~ (Previously Presented) The interactive system according to claim ~~57~~, wherein the system is comprised within a capillary tube system, a filter for physiological liquids, a dialyzer, a physiological replacement fluid, an enzyme delivery system, an arthroplasty or vascular prosthesis, or an artificial organ. 1

7 ~~44~~ (Previously Presented) The interactive system according to claim ~~57~~, wherein the active substance is selected from the group consisting of an anticoagulant, a metabolically active enzyme, an antibiotic and a synthetic pharmacon.

8 ~~45~~ (Previously Presented) The interactive system according to claim ~~44~~, wherein the anticoagulant is selected from the group consisting of heparin, hirudin, directly acting antithrombins and prothrombin.

9 ~~46~~ (Previously Presented) The interactive system according to claim ~~57~~, wherein the active substance further comprises an agent selected from an enzyme and a pharmaceutical composition.

47. to 51. (Canceled).

10 ~~52~~ (Previously Presented) The interactive system according to claim ~~57~~, wherein the linker is a (poly)ethylene glycol.

11 ~~53~~ (Previously Presented) The interactive system according to claim ~~57~~, wherein the active substance is coupled to the linker using a reactive derivative.

12 ~~54~~ (Previously Presented) The interactive system according to claim ~~57~~, wherein the reactive derivative is selected from the group consisting of succinimidyl succinate, succinimidyl propionate, nitrophenyl carbonate, tresylate, epoxides, aldehydes, isocyanates, maleimides.

55. (Canceled).

56. (Canceled).

1 ~~57~~ (Previously presented) An interactive system comprising:  
(a) a surface of a plastic material selected from the group consisting of a poly(meth)acrylate polymer, a polyvinyl ester polymer, copolymers thereof, and a

mixture of at least one polyalkyl(meth)acrylate with one or more of the group consisting of polystyrene, polyacrylonitrile, polycarbonate, and polysulfone; the material containing at least one structural element (A) which is the ester group of the acrylate or vinylester polymer, and

(b) a linker coupled to a pharmaceutically or physiologically active substance, the linker selected from the group consisting of a (poly)alkylene glycol, a (poly)alkylene imine, a (poly)alkylene amine, a polyoxazilin and a (poly)alkylene sulfide, wherein the linker is attached to the structural element (A) on the surface of the plastic material by a hydrogen bond which cannot be reversed by pH values in the range of 2 to 13 or temperatures up to 60° C.